ABOS | Acumen Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.1500 - 1.2400
52 Week Range	1.1000 - 4.06
Beta	-0.19
Implied Volatility	368.71%
IV Rank	42.67%
Day's Volume	117,427
Average Volume	255,966
Shares Outstanding	60,079,800
Market Cap	71,494,962
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.70
Forward P/E Ratio	-7.30
EPS	-1.71
1YR Price Target	16.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	51
Country	USA
Website	ABOS

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

ABOS's peers: TERN, XFOR, DAWN, HOOK, AMLX, INZY, MREO, ABSI, ACHV, ALZN, ANNX, ANVS, APLS, ARQT, ATRA, AUTL, BBIO, BIVI, BPMC, BTAI, CNTX, CRBP, CRMD, CRVS, CTXR, CYTK, DTIL, ELDN, ETNB, ETON, EYPT, GLSI, GLTO, GOSS, GNLX, HRTX, IDYA, IFRX, INKT, INVA, ITOS, JSPR, KPTI, LPTX, LQDA, MDGL, MDXH, MEIP, MESO, MGTX, MIRM, MRSN, NCNA, NERV, OCUL, PHAT, PRTG, PTGX, QSI, QURE, RARE, RCUS, RIGL, RXRX, SLNO, SPRB, TARS, TCRX, UBX, VKTX, VRCA, VRNA, VYGR, WVE, XBIT, MLTX, ERNA, IRON, COYA, GPCR

*Chart delayed

Analyzing fundamentals for ABOS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ABOS Fundamentals page.

Watching at ABOS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ABOS Technicals page.